Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jacl.2017.05.017 http://scihub22266oqcxt.onion/10.1016/j.jacl.2017.05.017 C5568906!5568906!28666713     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28666713.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Clin+Lipidol 2017 ; 11 (4): 964-71 Nephropedia Template TP {{tp|p=28666713|t=2017. GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia |pdf=|usr=}}{{28666713}} gab.com Text GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia JO: J Clin Lipidol http://www.kidney.de/pget.php?&tw=1&pmid=28666713 #FOAvip Background: GPIHBP1, a glycolipid-anchored protein of capillary endothelial cells, binds lipoprotein lipase (LPL) in the interstitial spaces and transports it to the capillary lumen. GPIHBP1 deficiency prevents LPL from reaching the capillary lumen, resulting in low intravascular LPL levels, impaired intravascular triglyceride processing, and severe hypertriglyceridemia (chylomicronemia). A recent study showed that some cases of hypertriglyceridemia are caused by autoantibodies against GPIHBP1 (?GPIHBP1 autoantibody syndrome?). Objective: Our objective was to gain additional insights into the frequency of the GPIHBP1 autoantibody syndrome in patients with unexplained chylomicronemia. Methods: We used ELISAs to screen for GPIHBP1 autoantibodies in 33 patients with unexplained chylomicronemia and then used western blots and immunocytochemistry studies to characterize the GPIHBP1 autoantibodies. Results: The plasma of one patient, a 36-year-old man with severe hypertriglyceridemia, contained GPIHBP1 autoantibodies. The autoantibodies, which were easily detectable by western blot, blocked the ability of GPIHBP1 to bind LPL. The plasma levels of LPL mass and activity were low. The patient had no history of autoimmune disease but his plasma was positive for antinuclear antibodies. Conclusions: One of 33 patients with unexplained chylomicronemia had the GPIHBP1 autoantibody syndrome. Additional studies in large lipid clinics will be helpful for better defining the frequency of this syndrome and for exploring the best strategies for treatment. Twit Text FOAVip GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia ????J Clin Lipidol http://www.kidney.de/pget.php?&tw=1&pmid=28666713 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28666713 #FOAvip English Wikipedia <ref>{{Cite pmid|28666713}}</ref> GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia #MMPMID28666713 Hu X; Dallinga-Thie GM; Hovingh GK; Chang SY; Sandoval NP; Dang TLP; Fukamachi I; Miyashita K; Nakajima K; Murakami M; Fong LG; Ploug M; Young SG; Beigneux AP J Clin Lipidol 2017[Jul]; 11 (4): 964-71 PMID28666713show ga Background: GPIHBP1, a glycolipid-anchored protein of capillary endothelial cells, binds lipoprotein lipase (LPL) in the interstitial spaces and transports it to the capillary lumen. GPIHBP1 deficiency prevents LPL from reaching the capillary lumen, resulting in low intravascular LPL levels, impaired intravascular triglyceride processing, and severe hypertriglyceridemia (chylomicronemia). A recent study showed that some cases of hypertriglyceridemia are caused by autoantibodies against GPIHBP1 (?GPIHBP1 autoantibody syndrome?). Objective: Our objective was to gain additional insights into the frequency of the GPIHBP1 autoantibody syndrome in patients with unexplained chylomicronemia. Methods: We used ELISAs to screen for GPIHBP1 autoantibodies in 33 patients with unexplained chylomicronemia and then used western blots and immunocytochemistry studies to characterize the GPIHBP1 autoantibodies. Results: The plasma of one patient, a 36-year-old man with severe hypertriglyceridemia, contained GPIHBP1 autoantibodies. The autoantibodies, which were easily detectable by western blot, blocked the ability of GPIHBP1 to bind LPL. The plasma levels of LPL mass and activity were low. The patient had no history of autoimmune disease but his plasma was positive for antinuclear antibodies. Conclusions: One of 33 patients with unexplained chylomicronemia had the GPIHBP1 autoantibody syndrome. Additional studies in large lipid clinics will be helpful for better defining the frequency of this syndrome and for exploring the best strategies for treatment. äGPIHBP1 autoantibodies in a patient with unexplained chylomicronemia (epmc).pdf DeepDyve Pubget Overpricing